Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Press Releases
ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
press release
December 2, 2021
GENEVA, Switzerland December 2, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…
Read moreObseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
press release
November 22, 2021
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant…
Read moreObseva Announces Appointment of Stephanie Brown to its Board of Directors
press release
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2021
May 28, 2021
ObsEva Annual General Meeting 2020
June 9, 2020
Upcoming Events
Sorry, there are no events available yes.
Stock Information
Latest Press Release
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
–Once daily linzagolix 200mg with ABTmet both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
